SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-016226
Filing Date
2023-05-01
Accepted
2023-05-01 16:02:36
Documents
7
Period of Report
2023-06-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A trvi_-_def_14a_-_2023_v1.htm DEF 14A 1161427
2 GRAPHIC img72671598_0.jpg GRAPHIC 55345
3 GRAPHIC img72671598_1.jpg GRAPHIC 20442
4 GRAPHIC img72671598_2.jpg GRAPHIC 55345
5 GRAPHIC img72671598_3.jpg GRAPHIC 20442
6 GRAPHIC img72671598_4.jpg GRAPHIC 144580
7 GRAPHIC img72671598_5.jpg GRAPHIC 96174
  Complete submission text file 0000950170-23-016226.txt   1694157
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38886 | Film No.: 23873468
SIC: 2834 Pharmaceutical Preparations